FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma

CONCLUSION: IHC is a good screening tool for negative and positive results. Any patient targeted for trastuzumab therapy should undergo confirmation of HER2/neu equivocal status by FISH analysis. We also suggest that if a non-classical FISH pattern is seen, the test should be repeated with a non-centromeric chromosome 17 reference locus probe for better treatment planning.

Source: Indian Journal of Cancer - May 1, 2019 Category: Cancer & Oncology Authors: Geeta Vikram Patil Okaly Dipti Panwar Kavitha Bidadli Lingappa Prasanna Kumari Abhishek Anand Prashantha Kumar Manju Hosur Chikkalingaiah Rekha Vijay Kumar Source Type: research